Division of Chr. Hansen Holding AS
Latest From ALK-Abello AS
Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.
The French firm's share price nearly halved on disappointing Phase III data for Viaskin while those of its rival, Aimmune, shot up, but all hope for the patch product is not yet lost.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
- Therapeutic Areas
- Immune Disorders
- Western Europe
- Parent & Subsidiaries
- Chr. Hansen Holding AS
- Senior Management
Carsten Hellmann, Pres. & CEO
Soren Jelert, EVP, CFO
Henrik Jacobi, EVP, R&D
- Contact Info
Phone: (45) 4574 7576
Boge Alle 6-8
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.